0001209191-22-035081.txt : 20220608
0001209191-22-035081.hdr.sgml : 20220608
20220608170108
ACCESSION NUMBER: 0001209191-22-035081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220607
FILED AS OF DATE: 20220608
DATE AS OF CHANGE: 20220608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Simson Jake
CENTRAL INDEX KEY: 0001863094
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40794
FILM NUMBER: 221004102
MAIL ADDRESS:
STREET 1: C/O JANUX THERAPEUTICS, INC.
STREET 2: 11099 N. TORREY PINES ROAD, SUITE 290
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DICE Therapeutics, Inc.
CENTRAL INDEX KEY: 0001645569
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472286244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 279 E. GRAND AVENUE, SUITE 300, LOBBY B
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-566-1402
MAIL ADDRESS:
STREET 1: 279 E. GRAND AVENUE, SUITE 300, LOBBY B
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: DiCE MOLECULES HOLDINGS, LLC
DATE OF NAME CHANGE: 20180725
FORMER COMPANY:
FORMER CONFORMED NAME: DiCE Molecules Holdings, LLC
DATE OF NAME CHANGE: 20150617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-07
0
0001645569
DICE Therapeutics, Inc.
DICE
0001863094
Simson Jake
C/O DICE THERAPEUTICS, INC.
400 EAST JAMIE COURT, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Stock Option (right to buy Common Stock)
14.98
2022-06-07
4
A
0
21250
0.00
A
2032-06-06
Common Stock
21250
21250
D
The option vests on the earlier to occur of: (i) the one-year anniversary of the grant date and (ii) the subsequent annual meeting of the Registrant's stockholders, in each case, subject to the Reporting Holder's continued service to the Registrant.
Under the Reporting Holder's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Holder holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Holder is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Holder therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
/s/ Scott Robertson as attorney-in-fact for Jake Simson
2022-06-08